期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

树突状细胞促成熟因子研究进展 被引量：1

Progress in maturation-promoting factor of dendritic cells
下载PDF
导出
摘要 树突状细胞(DC)是体内抗原递呈功能最强、惟一能激活幼稚T淋巴细胞的专职抗原递呈细胞,在肿瘤免疫中的作用日益受到重视。目前临床所用的DC多是从外周血单个核细胞经体外培养而来。体外培养第一阶段的方法已得到公认即GM-CSF+TL-4,由此得到不成熟DC。第二阶段即用不同促成熟因子作用于不成熟DC,使之成熟。目前促成熟因子种类繁多,效果亦众说纷纭。现就常用的促成熟因子的作用机制及其效果作一综述。
作者 蒲骁麟 束永前
机构地区 江苏省人民医院南京医科大学第一附属医院肿瘤中心
出处 《国外医学（肿瘤学分册）》 2005年第9期646-649,共4页 Foreign Medical Sciences (Cancer Section)
基金 江苏省卫生厅医学科技发展重大课题基金资助项目(H200211)
关键词 树突细胞 细胞活素类 细胞培养
分类号 R392 [医药卫生—免疫学]
  • 相关文献

参考文献20

  • 1Bancher J, Steinman RM. Dendritic cells and the control of immunity.Nature, 1998,392(6673 ) :245-252.
  • 2Chen X, Regn S, Raffegerst S, et al. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a special anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol,2000,111 ( 2 ) :596-607.
  • 3Paquette RL, Hsu N, Said J, et al. Interferon- alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia ,2002,16 ( 8 ): 1484-1489.
  • 4Wang C,AI Omar HM,Kadvanyil,et al. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-α. Exp Hematol, 1999,27 (7): 1176-1184.
  • 5Santini SM, Lapenta C, Logozzi M, et al. Type Ⅰ interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med, 2000, 191(10) :1777-1788.
  • 6Jarrossay D, Napolitani G, Colonna M, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol, 2001,31 ( 11 ) :3388-3393.
  • 7Uehori J, Matsumoto M, Tsuji S, et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun,2003,71 (8) :4238-4249.
  • 8Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigen. J Exp Med , 2001,194 ( 6 ): 863- 869.
  • 9Cheadle E J, Selby PJ, Jackson AM. Mycobacterium bovis bacillus Calmette-Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism. Immunology,2003,108( 1 ) :79-88.
  • 10Kaisho T,Akira S. Dendritic cell function in Toll-like receptor and MyD88- knockout mice. Trends Immunol,2001,22 ( 2 ) :78-83.

二级参考文献15

  • 1[1]Schuler G, Steinman RM. Dendritic cells as adjuvants for immunemediated resistance to tumors[J]. J Exp Med, 1997, 186: 1183-1187.
  • 2[2]Hart DN. Dendritic cells: Unique leukocyte populations which control the primary immune response [ J ]. Blood, 1997, 90:3245-3287.
  • 3[3]Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines[J]. Stem cells, 1997, 15:94-103.
  • 4[4]Brossart P, Grunebach F, Stuhler G, et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor[ J]. Blood, 1998, 92: 4238-4247.
  • 5[5]Mackey MF, Gunn JR, Maliszewsky C, et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol, 1998; 16: 2094-2098.
  • 6[6]Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophage[ J]. Eur J Immunol, 1998, 28: 359-369.
  • 7[7]Buelens C, et al. Interleukin 10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with IL-4 and GM-CSF[ J]. Eur J Immunol, 1997,27: 756-762.
  • 8[8]Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells[J]. Nat Med, 1996, 2: 52-58.
  • 9[9]Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy[J]. Annu Rev Med, 1999, 50: 507-529.
  • 10[10]Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects[ J]. Br J Haematol, 2000, 108: 805-816.

共引文献11

同被引文献24

  • 1刘宁.树突状细胞的研究进展[J].国际医药卫生导报,2006,12(6):121-123. 被引量：5
  • 2罗道升,戴宇平.树突状细胞相关基础研究进展[J].国外医学（免疫学分册）,2005,28(1):51-55. 被引量：18
  • 3熊菲,程茜.树突状细胞培养技术的研究进展[J].国外医学（临床生物化学与检验学分册）,2005,26(4):238-240. 被引量：8
  • 4崔永春,李建强,崔莲仙（审校）,何维（审校）.CD1分子的研究进展[J].国际免疫学杂志,2006,29(3):129-132. 被引量：14
  • 5Tomonori I, Shimoyama S, Kang L, et al. The CD8^+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo [J]. J Exp Med, 2002, 195(10): 1289.
  • 6Lutz M B, Suri R M. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo [J]. Eur Immunol, 2000, 30(7): 1813-1822.
  • 7Araki H, Katayama N, Litami H, et al. Efficient exvivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trailss [J]. Br J Haaematol, 2001, 114(3): 681-689.
  • 8Agnes Jamin, Stephane Gorin, Marie-Frederique Le Potier, et al. Characterization of conventional and plasmacytoid dendritic cells in swine secondary lymphoid organs and blood [J]. Vet Immunol Immunopathol, 2006, (114): 224-237.
  • 9Fongl, Engleman E G. Dendritic cells in cancer immunotherapy [J]. Ann Rev immunol, 2000, 18: 245-273.
  • 10Bancher J, Steinman R M. Dendritic cells and the control of immunity [J]. Nature, 1998, 39(6673): 245-252.

引证文献1

二级引证文献6

国外医学（肿瘤学分册）
2005年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部